OncoMatch/Clinical Trials/NCT06162221
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Is NCT06162221 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments for non-small cell lung cancer, nsclc.
Treatment: RMC-6291 · RMC-6236 · Pembrolizumab · Cisplatin · Carboplatin · Pemetrexed · RMC-9805 — The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other. The first four subprotocols include the following: Subprotocol A: RMC-6291 +/- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C: RMC-9805 +/- RMC-6236 + SOC Subprotocol D: RMC-9805
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Tumor Agnostic
Biomarker criteria
Required: KRAS G12C mutation
KRAS G12C-mutated solid tumor malignancy (Subprotocol A)
Required: KRAS G12D mutation
RAS G12D-mutated NSCLC (Subprotocol C and Subprotocol D)
Required: NRAS mutation
RAS-mutated NSCLC (Subprotocol B)
Required: HRAS mutation
RAS-mutated NSCLC (Subprotocol B)
Required: KRAS mutation
RAS-mutated NSCLC (Subprotocol B)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapy — appropriate for tumor type and stage
Received prior standard therapy appropriate for tumor type and stage
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function as outlined by the study
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Banner MD Anderson Cancer Center · Gilbert, Arizona
- City of Hope - Duarte · Duarte, California
- City of Hope - Lennar · Irvine, California
- UC Davis, Davis Comprehensive Cancer Center · Sacramento, California
- University of California, San Diego Moores Cancer Center · San Diego, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06162221 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received standard therapy.
Does this trial require KRAS?
Yes, KRAS G12C mutation is a required biomarker for enrollment.
Does this trial require KRAS?
Yes, KRAS G12D mutation is a required biomarker for enrollment.
Does this trial require NRAS?
Yes, NRAS mutation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages